Ripoll E, Arribas I, Relea P, Varela L, Villa L F, Revilla M, Rico H
Central Laboratory Príncipe de Asturias, University Hospital, University of Alcalá de Henares, Madrid, Spain.
Calcif Tissue Int. 1995 Oct;57(4):272-6. doi: 10.1007/BF00298882.
Beta2-microglobulin has been observed to behave as a biological marker of bone remodeling. We measured beta2-microglobulin and tartrate-resistant acid phosphatase (TRAP), a specific biological marker of bone remodeling, in 225 women: healthy premenopausal controls, healthy postmenopausal control, and patients with diseases characterized by enhanced bone turnover (postmenopausal osteoporosis, primary hyperparathyroidism, primary hyperthyroidism, polyostotic Paget's bone disease), and in other Paget's group before and after calcitonin treatment. Beta2-microglobulin levels differed significantly between the healthy premenopausal women (n = 20) compared with all the other groups. However, beta2-microglobulin levels did not differ significantly between healthy postmenopausal women (n = 38) and patient's with Paget's bone disease (n = 40)(P = 0.5095), or between women with postmenopausal osteoporosis (n = 30) and women with hyperthyroidism (n = 20)(P = 0.7890). TRAP concentrations differed significantly in all the groups paired except for women with Paget's bone disease and women with either hyperparathyroidism or hyperthyroidism (P = 0.5179 and 0.6993, respectively); likewise, TRAP levels did not differ significantly between the women with hyperparathyroidism and those with hypothyroidism (P = 0.7804). After calcitonin treatment, there was a 22% increase in beta2-microglobulin, a 17% decrease in TRAP, and a 39% decrease in alkaline phosphatase, all of which were significant at P < 0.0001. Our findings indicate that serum beta2-microglobulin, like osteocalcin, behaves as a biological marker of remodeling in a number of diseases with enhanced bone remodeling but not in Paget's bone disease.
已观察到β2-微球蛋白可作为骨重塑的生物学标志物。我们在225名女性中测量了β2-微球蛋白和抗酒石酸酸性磷酸酶（TRAP，一种骨重塑的特异性生物学标志物），这些女性包括：健康的绝经前对照者、健康的绝经后对照者，以及以骨转换增强为特征的疾病患者（绝经后骨质疏松症、原发性甲状旁腺功能亢进症、原发性甲状腺功能亢进症、多骨型佩吉特骨病），并在降钙素治疗前后对其他佩吉特病组进行了测量。与所有其他组相比，健康绝经前女性（n = 20）的β2-微球蛋白水平存在显著差异。然而，健康绝经后女性（n = 38）与佩吉特骨病患者（n = 40）之间的β2-微球蛋白水平无显著差异（P = 0.5095），绝经后骨质疏松症女性（n = 30）与甲状腺功能亢进症女性（n = 20）之间也无显著差异（P = 0.7890）。除佩吉特骨病女性与甲状旁腺功能亢进症或甲状腺功能亢进症女性外（分别为P = 0.5179和0.6993），所有配对组中的TRAP浓度均存在显著差异；同样，甲状旁腺功能亢进症女性与甲状腺功能减退症女性之间的TRAP水平也无显著差异（P = 0.7804）。降钙素治疗后，β2-微球蛋白增加了22%，TRAP降低了17%，碱性磷酸酶降低了39%，所有这些在P < 0.0001时均具有显著性。我们的数据表明，血清β2-微球蛋白与骨钙素一样，在许多骨重塑增强的疾病中可作为重塑的生物学标志物，但在佩吉特骨病中并非如此。
